Tarakji Khaldoun G, Patel Divyang, Krishnaswamy Amar, Hussein Ayman, Saliba Walid, Wilkoff Bruce L, Wolski Kathy, Svensson Lars, Wazni Oussama M, Kapadia Samir R
Heart, Vascular and Thoracic Institute, Cleveland Clinic, Cleveland, Ohio.
Heart, Vascular and Thoracic Institute, Cleveland Clinic, Cleveland, Ohio.
Heart Rhythm. 2022 Mar;19(3):381-388. doi: 10.1016/j.hrthm.2021.11.020. Epub 2021 Nov 18.
Bradyarrhythmias leading to permanent pacemaker (PPM) implantation continue to be a complication after transcatheter aortic valve replacement (TAVR).
The purpose of this study was to assess the prevalence of bradyarrhythmias using an electrocardiographic (ECG) extended rhythm recording in patients pre- and post-TAVR and whether they can predict the need for PPM.
This was a prospective single-center study in patients undergoing TAVR. Patients received an ECG patch for 2 weeks pre-, immediately post-, and 2-3 months post-TAVR. Caring physicians were blinded to the results of the patch except when predefined urgent arrhythmias were detected. The main outcome was the need for PPM implantation after TAVR.
We enrolled 110 patients, of whom 96 underwent TAVR and were included in the final analysis. Bradyarrhythmias, defined as a pause of 3 seconds or more, occurred in 5.2%, 12.7%, and 7% of patients pre-, immediately post-, and 2-3 months post-TAVR, respectively. PPM implantation occurred in 12 patients (12.5%), of whom 9 (9.4%) underwent implantation during their index hospitalization while 3 (3.1%) required implantation postdischarge for indications other than heart block. No patients required PPM after receiving an ECG patch 2-3 months post-TAVR. Significant baseline predictors for the need for PPM included the presence of right bundle branch block and increased QRS duration. Bradyarrhythmias detected by the ECG patch did not predict the need for PPM at either the index hospitalization or the follow-up period.
Bradyarrhythmias are common and can be detected with extended ECG monitoring before and after TAVR; however, in our study they did not predict the need for PPM after TAVR (ClinicalTrials.gov identifier: NCT03180073).
导致永久性起搏器(PPM)植入的缓慢性心律失常仍然是经导管主动脉瓣置换术(TAVR)后的一种并发症。
本研究的目的是使用心电图(ECG)延长心律记录评估TAVR术前和术后患者缓慢性心律失常的患病率,以及它们是否能够预测PPM的需求。
这是一项针对接受TAVR患者的前瞻性单中心研究。患者在TAVR术前2周、术后即刻以及术后2 - 3个月佩戴ECG贴片2周。除检测到预定义的紧急心律失常外,负责的医生对贴片结果不知情。主要结局是TAVR术后PPM植入的需求。
我们纳入了110例患者,其中96例接受了TAVR并纳入最终分析。分别有5.2%、12.7%和7%的患者在TAVR术前、术后即刻以及术后2 - 3个月发生了定义为停顿3秒或更长时间的缓慢性心律失常。12例患者(12.5%)接受了PPM植入,其中9例(9.4%)在首次住院期间植入,3例(3.1%)出院后因心脏传导阻滞以外的指征需要植入。TAVR术后2 - 3个月接受ECG贴片检查后,没有患者需要PPM。PPM需求的显著基线预测因素包括右束支传导阻滞的存在和QRS时限延长。ECG贴片检测到的缓慢性心律失常在首次住院或随访期间均未预测PPM的需求。
缓慢性心律失常很常见,并且可以通过TAVR前后的延长ECG监测检测到;然而,在我们的研究中,它们并未预测TAVR术后PPM的需求(ClinicalTrials.gov标识符:NCT03180073)。